Miriam Mikhail

Dr. Miriam Mikhail

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2022 in Seminars in Nuclear Medicine
Verified
Journal Article
Open access
Francesco GiammarileFrancesco Giammarile
Francesco Giammarile
SVSergi Vidal-Sicart
Sergi Vidal-Sicart
DPDiana Paez
Diana Paez
OPOlivier Pellet
Olivier Pellet
EEEstrada-Lobato Enrique
Estrada-Lobato Enrique
GMGiuliano Mariani
Giuliano Mariani
Breast cancer is the most frequent cancer diagnosed in women worldwide. Accurate lymph node staging is essential for both prognosis (of early-stage disease) and treatment (for regional control of disease) in patients with breast cancer. The sentinel lymph nodes are the regional nodes that directly drain lymph from the primary tumor. No imaging modality is accurate enough to detect lymph node metastases when a primary breast cancer is at an early stage (I or II), but sentinel lymph node biopsy is a highly reliable method for screening axillary nodes and for identifying metastatic (including micro-metastatic) disease in regional lymph nodes. Despite the widespread use of sentinel lymph node biopsy for early-stage breast cancer, relevant variations have been described regarding practical aspects of the procedure, and some variability has initially been reported regarding the rates of intraoperative sentinel lymph node identification and of false-negative findings, most likely because of differences in the size of the populations being investigated and in lymphatic mapping techniques. Nevertheless, using adequate learning curves and once a multidisciplinary team is experienced with the procedure, improved levels of accuracy are achieved.

6 February 2024 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Open access
PDF file
Francesco GiammarileFrancesco Giammarile
Francesco Giammarile
PKPeter Knoll
Peter Knoll
JKJolanta Kunikowska
Jolanta Kunikowska
DPDiana Paez
Diana Paez
ELEnrique Estrada Lobato
Enrique Estrada Lobato
RBRoberto Delgado Bolton
Roberto Delgado Bolton
Background: In the rapidly evolving field of nuclear medicine, the paramount importance of radiation protection, safety, and quality systems cannot be overstated. This document provides a comprehensive analysis of the intricate regulatory frameworks and guidelines, meticulously crafted and updated by national and international regulatory bodies to ensure the utmost safety and efficiency in the practice of nuclear medicine. Methods: We explore the dynamic nature of these regulations, emphasizing their adaptability in accommodating technological advancements and the integration of nuclear medicine with other medical and scientific disciplines. Results: Audits, both internal and external, are spotlighted for their pivotal role in assessing and ensuring compliance with established standards, promoting a culture of continuous improvement and excellence. We delve into the significant contributions of entities like the International Atomic Energy Agency (IAEA) and relevant professional societies in offering universally applicable guidelines that amalgamate the latest in scientific research, ethical considerations, and practical applicability. Conclusions: The document underscores the essence of international collaborations in pooling expertise, resources, and insights, fostering a global community of practice where knowledge and innovations are shared. Readers will gain an in-depth understanding of the practical applications, challenges, and opportunities presented by these regulatory frameworks and audit processes. The ultimate goal is to inspire and inform ongoing efforts to enhance safety, quality, and effectiveness in nuclear medicine globally.

25 October 2021 in Clinical and Translational Imaging
Verified
Journal Article
Open access
PDF file
AGAnna Grigoryan
Anna Grigoryan
SBSalah Bouyoucef
Salah Bouyoucef
Mike SathekgeMike Sathekge
Mike Sathekge
MVMariza Vorster
Mariza Vorster
POPilar Orellana
Pilar Orellana
Francesco GiammarileFrancesco Giammarile
Francesco Giammarile

17 April 2025 in World Journal of Nuclear Medicine
Verified
Journal Article
Open access
PDF file
ABAnita Brink
Anita Brink
JCJuliano J. Cerci
Juliano J. Cerci
Francesco GiammarileFrancesco Giammarile
Francesco Giammarile
DYDanylo Yurystovskyi
Danylo Yurystovskyi
AKAruna Korde
Aruna Korde
DPDiana Paez
Diana Paez
The global expansion of theranostics, a field combining molecular imaging and targeted therapy, has accelerated with the Food and Drug Administration approvals of Lutathera and Pluvicto. However, significant challenges hinder equitable access, particularly in low- and middle-income countries (LMICs). These include infrastructure limitations, such as the high cost of gamma cameras, positron emission tomography/computed tomography scanners, cyclotrons, and maintenance, as well as disparities in the availability of radiopharmaceuticals. In LMICs, one single-photon emission computerized tomography scanner may serve 33 million people, compared with 57,000 in high-income countries. Furthermore, shortages of key isotopes like 99Mo and 177Lu highlight vulnerabilities in global supply chains. Staffing and training are critical issues, as delivering theranostic services requires specialized teams that are often scarce in LMICs. The International Atomic Energy Agency (IAEA) addresses these challenges by offering training programs, developing databases like IMAGINE and NUMDAB, and fostering technical cooperation among member states. To improve access to theranostic services, strategies such as using alternative imaging methods and enhancing local radiopharmaceutical production are recommended. The IAEA's Rays of Hope initiative aims to strengthen regional capacities, improve infrastructure, and address the critical shortage of trained professionals. A coordinated global effort is essential to overcome these barriers, reduce costs, and ensure equitable access to theranostics, particularly in resource-limited settings.

1 June 2022 in JCO Global Oncology
Verified
Journal Article
Open access
MMMiriam Mikhail
Miriam Mikhail
DPDiana Paez
Diana Paez
LSLawrence N. Shulman
Lawrence N. Shulman
MGMathias Guckenberger
Mathias Guckenberger
JDJean-Yves Douillard
Jean-Yves Douillard
MWMay Abdel Wahab
May Abdel Wahab
PURPOSE: Key to achieving better population-based outcomes for patients with lung cancer is the improvement of medical imaging and nuclear medicine infrastructure globally. This paper aims to outline why and spark relevant health systems strengthening. METHODS: The paper synthesizes the global lung cancer landscape, imaging referral guidelines (including resource-stratified ones), the reliance of TNM staging upon imaging, relevant multinational health technology assessments, and precisely how treatment selection and in turn patient outcomes hinge upon imaging findings. The final discussion presents data on current global gaps in both diagnostics (including imaging) and therapies and how, informed by such data, improved population-based outcomes are tangible through strategic planning. RESULTS: Imaging findings are central to appropriate lung cancer patient management and can variably lead to life-prolonging interventions and/or to life-enhancing palliative measures. Early-stage lung cancer can be treated with curative intent but, unfortunately, most patients with lung cancer still present at advanced stages and many patients lack access to both diagnostics and therapies. Furthermore, half of lung cancer cases occur in low- and middle-income countries. The role of medical imaging and nuclear medicine in lung cancer management, as outlined herein, may help inform strategic planning. CONCLUSION: Lung cancer is the number one cancer killer worldwide. The essential role that medical imaging and nuclear medicine play in early diagnosis and disease staging cannot be overstated, pivotal in selecting the many patients for whom measurably improved outcomes are attainable. Prevention synergized with patient-centered, compassionate, high-quality lung cancer management provision mandate that strategic population-based planning, including universal health coverage strategies, should extend well beyond the scope of disease prevention to include both curative and noncurative treatment options for the millions afflicted with lung cancer.

29 March 2024 in Journal of Cancer Policy
Verified
Journal Article
Closed access
MMMiriam Mikhail
Miriam Mikhail
LCLisbeth Cordero
Lisbeth Cordero
YLYolande Lievens
Yolande Lievens
Akram Al-IbraheemAkram Al-Ibraheem
Akram Al-Ibraheem
JUJean-Luc Urbain
Jean-Luc Urbain
MAMay Abdel-Wahab
May Abdel-Wahab